Proof of efficacy is not enough: contemporary management of patients with metastatic renal cell carcinoma with targeted therapy
- PMID: 22987077
- DOI: 10.1200/JCO.2012.43.7376
Proof of efficacy is not enough: contemporary management of patients with metastatic renal cell carcinoma with targeted therapy
Comment on
-
Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.J Clin Oncol. 2012 May 10;30(14):1678-85. doi: 10.1200/JCO.2011.35.3524. Epub 2012 Apr 9. J Clin Oncol. 2012. PMID: 22493422 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical